Format

Send to

Choose Destination
Eur Urol. 2008 Nov;54(5):1097-106. Epub 2007 Nov 26.

ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.

Author information

1
Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Abstract

OBJECTIVES:

A disintegrin and metalloprotease (ADAM) 9 has been implicated in tumour progression of prostate cancer. We evaluated the expression of ADAM9 on protein and messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following prostatectomy and correlated the findings with clinicopathological parameters including prostate-specific antigen (PSA) relapse times.

METHODS:

We immunostained 198 clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analysed via quantitative reverse transcriptase-polymerase chain reaction.

RESULTS:

ADAM9 was significantly upregulated in prostate cancer compared with normal tissue on mRNA and protein level. ADAM9 protein expression was significantly associated with shortened PSA relapse-free survival in univariate and multivariate analyses, particularly in patients who had received prior androgen ablation.

CONCLUSIONS:

ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse-free survival following radical prostatectomy. Further studies are needed to verify its role as a predictive marker of response to androgen ablation.

PMID:
18061337
DOI:
10.1016/j.eururo.2007.11.034
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center